When was Debut founded?

Debut was founded in 2019 and raised its 1st funding round 1 year after it was founded.

Where is Debut located?

Debut is headquartered in San Diego, United States. It is registered at 86-90 PAUL STREET,LONDON,ENGLAND,EC2A 4NE.

Who is the current CEO of Debut?

Joshua Britton of Debut. They have also founded 1 company.

Which legal entities is Debut associated with?

Debut is associated with SNAAK LTD and 1 other.

How many employees does Debut have?

As of Sep 30, 2026, the latest employee count at Debut is 96.

Is Debut a funded company?

Debut is a funded company, having raised a total of $126M across 8 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jan 06, 2020.

How much is Debut worth?

The latest valuation of Debut is $***** as of Mar 03, 2023.

When was the latest funding round of Debut?

Debut's latest funding was a $***** Series B round on Aug 26, 2025, with participation from 6 investors.

Where does Debut rank among its competitors?

Debut ranks 4th amongst 92 active competitors, of which 17 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was EnginZyme, which secured $7.6M in Sep, 2026.

Who are the top competitors of Debut?

Debut's top competitors include Codexis, EnginZyme and Immobazyme. Among them, EnginZyme secured the most recent funding round in September, 2026.

Debut - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider and manufacturer of enzymes for biotherapeutic creation and modification. The company offers a range of enzymes that are used in the biotech industry for immobilization and other therapeutic applications. The company also provides continuous biomanufacturing cartridges, immobilized cells, immobilized enzymes for continuous biomanufacturing.

Website: www.debutbiotech.com/
Social
Email ID: *****@debutbiotech.com
Registered Address: 86-90 PAUL STREET,LONDON,ENGLAND,EC2A 4NE

Key Metrics

Founded Year

2019

Location

San Diego, United States

Stage

Series B

Total Funding

$126M in 8 rounds

Latest Funding Round

Series B, Aug 26, 2025, $*****

Post Money Valuation

$***** as on Mar 03, 2023

Investors

BOLD & 17 more

Ranked

4^th among 92 active competitors

Employee Count

96 as on Sep 30, 2026

Similar Companies

Codexis & 104 more

View Debut's full profile

Debut is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
SNAAK LTD CIN: 7413775 , United Kingdom, Active	Oct 19, 2010	£0 - £1M (As on Oct 25, 2022)	1 (As on Oct 25, 2022)
Debut Biotechnology, Inc. CIN: 84-1804621 , United States, Active	May 09, 2019	-	18 (As on Dec 31, 2021)	-

Debut has raised a total funding of $126M over 8 rounds. Its first funding round was on Jan 06, 2020. Its latest funding round was a Series B round on Aug 26, 2025 for $*****. 6 investors participated in its latest round. Debut has 18 institutional investors.

Here is the list of recent funding rounds of Debut:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 26, 2025	4529151	Series B	4685986	6235352	4266779	2647559
Oct 19, 2023	4166137	Series B	3068481	2680695	1275927	9019751
Jun 12, 2023	2539245	Series B	5049122	7273165	INX International Ink	8486714

Access funding benchmarks and valuations. Sign up today!

View details of Debut's funding rounds and investors

The founders of Debut are Joshua Britton and Gregory Weiss. Joshua Britton is the CEO of Debut.

Here are the details of Debut's key team members:

Joshua Britton: Co-Founder & CEO of Debut. They serve on the board of 1 company.
Contact Info: 1 email address
Gregory Weiss: Co-Founder of Debut.

Debut's Board of Directors

Debut's board has 5 active members. Joshua Britton, Daniel Phillips, Cain A. McClary, CORINNA CHEN and GREGORY A. WEISS are independent board members.

Here is the list of Debut's board of directors:

Name	Type	Representing	Status	Duration
Joshua Britton	Independent board member	-	Current	6y 8m
wtguys{	Independent board member	-	Current	5y 6m
ydp{h{b	Independent board member	-	Current	1y 9m
bjbsssw	Independent board member	-	Current	9y 9m
rflpycb	Independent board member	-	Current	5y 9m

View details of Debut's Founder profiles and Board Members

Debut's employee count trend

Debut has 96 employees as of Sep 26. Here is Debut's employee count trend over the years:

Uncover Debut's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Debut include Codexis, EnginZyme and Immobazyme. Here is the list of Top 10 competitors of Debut, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Codexis 2002, Redwood City (United States), Public	Developer of high-performance enzymes for drug discovery	$111M	Vivo Capital, Malaysian Life Sciences Capital Fund ... & 12 others	68/100
2nd	EnginZyme 2014, Stockholm (Sweden), Series B	Developer of immobilized enzymes	$42.3M	Industrifonden, Sofinnova Partners & 8 others	57/100
3rd	Immobazyme 2019, Stellenbosch (South Africa), Series A	Developer of enzyme immobilisation technology	$2.9M	UTF, Fireball Capital & 2 others	51/100
4th	Debut 2019, San Diego (United States), Series B	Provider and manufacturer of enzymes for biotherapeutic creation and modification	$126M	EDBI, Cultivian Sandbox & 16 others	52/100
5th	Genovis 1999, Lund (Sweden), Public	Develps enzymes for antibodies	-	Northislet, Hansa Biopharma	50/100
6th	Allozymes 2019, Singapore (Singapore), Series A	Developer of enzyme engineering platform for biosolutions across diverse industries	$20M	Seventure Partners, Xora Innovation & 8 others	48/100
7th	Twelve Bio 2019, Copenhagen (Denmark), Acquired	Developer of CRISPER technology based diagnostics and therapeutics	$2.57M	Arix Bioscience, BioInnovation Institute	45/100
8th	Nucleus Biologics 2016, San Diego (United States), Funding Raised	Cell culture solutions provider accelerating cell and gene therapy development	-	-	43/100
9th	New England Biolabs 1970, Ipswich (United Kingdom), Funding Raised	Molecular biology reagents company	-	NIH SBIR/STTR, Massachusetts Life Sciences Center ... & 2 others	43/100
10th	Creative Enzymes 2011, New York City (United States), Unfunded	Enzymes, probiotics, and extracts for research, diagnostics, and industrial applications	-	-	41/100